ストックスクリーナーアプリを入手
14.62
3.39%
0.48
アフターアワーズ：
14.67
0.05
+0.34%
Oculis Holding Ag (OCS) 最新ニュース
(OCS) Investment Analysis - Stock Traders Daily
Is Oculis Holding (OCS) Top Performing European Stock Heading into 2025? - Insider Monkey
Oculis to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Oculis (OCS) to Present at Stifel Healthcare Conference: CFO Fireside Chat Announced | OCS Stock News - StockTitan
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
HC Wainwright Reiterates Buy Rating for Oculis (NASDAQ:OCS) - MarketBeat
Oculis Holding AG Reports Q3 2024 Financial Progress - TipRanks
Oculis Holding’s Financial Struggles Amid Asset Growth - TipRanks
Oculis Holding AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Oculis Reports Q3 2024 Financial Results and Provides Company Updates - GlobeNewswire
Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins - GlobeNewswire Inc.
Oculis (OCS) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Oculis (NASDAQ:OCS) Hits New 12-Month HighWhat's Next? - MarketBeat
Oculis: Lack Of Coverage Only Real Risk For This Solid Company - Seeking Alpha
abrdn plc Sells 279,879 Shares of Oculis Holding AG (NASDAQ:OCS) - MarketBeat
Oculis (NASDAQ:OCS) Sees Strong Trading VolumeHere's Why - MarketBeat
Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last? - MSN
Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39% - Yahoo Finance
Oculis (NASDAQ:OCS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Short Interest in Oculis Holding AG (NASDAQ:OCS) Grows By 133.7% - MarketBeat
Trading (OCS) With Integrated Risk Controls - Stock Traders Daily
Oculis (NASDAQ:OCS) Shares Gap DownHere's Why - MarketBeat
Oculis (NASDAQ:OCS) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Oculis (NASDAQ:OCS) - MarketBeat
Financial Comparison: Oculis (NASDAQ:OCS) and Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Oculis (NASDAQ:OCS) Reaches New 52-Week HighTime to Buy? - MarketBeat
Oculis Holding AG's (NASDAQ:OCS) market cap touched US$586m last week, benefiting both individual investors who own 55% as well as institutions - Simply Wall St
Oculis accelerates patient enrollment for both Phase 3 DIAMOND trials - TipRanks
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees - StockTitan
Oculis (NASDAQ:OCS) Trading Up 4.8%Here's What Happened - MarketBeat
Oculis Accelerates Enrollment in both DIAMOND Phase 3 - GlobeNewswire
OCSOculis Holding AG Ordinary shares Latest Stock News & Market Updates - StockTitan
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema - GlobeNewswire
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 - StockTitan
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis - RTTNews
Oculis (NASDAQ:OCS) Hits New 52-Week High – Here’s What Happened - Defense World
Oculis (NASDAQ:OCS) Hits New 52-Week HighWhat's Next? - MarketBeat
Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains? - Yahoo Finance
Objective long/short (OCS) Report - Stock Traders Daily
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer - Vision Monday
Oculis Holding AG (NASDAQ:OCS) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Reviewing Oculis (NASDAQ:OCS) & Journey Medical (NASDAQ:DERM) - Defense World
Learn to Evaluate (OCS) using the Charts - Stock Traders Daily
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):